14 Jan 2021
Vivantis Technologies announces ViPrimePLUS 2019-nCoV Multiplex RT-PCR Kit and GF-1 Viral Nucleic Acid Extraction Kit gain CE-IVD certification and commercial availability of these kits in Europe.
Developed and manufactured by Vivantis’s team in Malaysia, ViPrimePLUS 2019-nCoV Multiplex RT-PCR Kit deploys Taqman probe-based real-time reverse transcription polymerase chain reaction (RT-qPCR) technology for qualitative detection of the SARS-COV-2 or 2019-nCoV virus genome in clinical samples isolated from nasopharyngeal and oropharyngeal swab, bronchoalveolar lavage, tracheal aspirate, nasopharyngeal aspirate or nasal wash, sputum and serum. This kit is compatible with most of the real-time PCR instruments in the market such as Bio-Rad CFX96TM Real-Time PCR Detection System and QuantStudioTM Real-Time PCR System. ViPrimePLUS 2019-nCoV Multiplex RT-PCR Kit can also be used with GF-1 Viral Nucleic Acid Extraction Kit which utilizes mini-spin columns for rapid centrifugation-based processing of viral samples, eliminating the need of toxic or organic-based extraction. The GF-1 purification system contains essential components and optimized buffers to efficiently isolate and purify viral DNA and/or RNA from a broad range of sample materials, including serum, plasma, body fluid, virus-infected cell culture supernatant, VTM buffers consists of virus infected swabs and saliva.
“Securing the CE-IVD mark is an important milestone for Vivantis in advancing our efforts to elevate COVID-19 testing capacity for frontliners in healthcare industry but also to support and accelerating advancement in research & development in relating to new viral diseases. We are committed to work together with our distribution partners and customers to expand the availability of SAR-CoV-2 diagnostic testing to meet the global market demand,” said Law Eng Lim, CEO of Vivantis Technologies.
